Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33705695

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Apr
First author
Shi T

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Apr;22(4):412-413. doi: 10.1016/S1470-2045(21)00024-3.
    note
    Source null
    related pmid
    33705694
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Jun;22(6):e230. doi: 10.1016/S1470-2045(21)00181-9.
    note
    Source null
    related pmid
    34087139
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Jun;22(6):e231. doi: 10.1016/S1470-2045(21)00187-X.
    note
    Source null
    related pmid
    34087140
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2021 Jun;22(6):e232. doi: 10.1016/S1470-2045(21)00277-1.
    note
    Source null
    related pmid
    34087141
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2021 Jun;22(6):e233. doi: 10.1016/S1470-2045(21)00294-1.
    note
    Source null
    related pmid
    34087142
    relationship
    Comment in

Authors and identifiers

  1. name
    Shi T
    type
    Author
  2. name
    Zhu J
    type
    Author
  3. name
    Feng Y
    type
    Author
  4. name
    Tu D
    type
    Author
  5. name
    Zhang Y
    type
    Author
  6. name
    Zhang P
    type
    Author
  7. name
    Jia H
    type
    Author
  8. name
    Huang X
    type
    Author
  9. name
    Cai Y
    type
    Author
  10. name
    Yin S
    type
    Author
  11. name
    Jiang R
    type
    Author
  12. name
    Tian W
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Shi T
    type
    Author
  2. name
    Zhu J
    type
    Author
  3. name
    Feng Y
    type
    Author
  4. name
    Tu D
    type
    Author
  5. name
    Zhang Y
    type
    Author
  6. name
    Zhang P
    type
    Author
  7. name
    Jia H
    type
    Author
  8. name
    Huang X
    type
    Author
  9. name
    Cai Y
    type
    Author
  10. name
    Yin S
    type
    Author
  11. name
    Jiang R
    type
    Author
  12. name
    Tian W
    type
    Author
bibliography ids
  1. nci-bib-a2c9ceb9de1a2e1cd179c7af
book metadata
content sha256
017e8fe4c1f1cdf42aacde5a96fb73acd93ac76df15499001cc3e1ff068b9fca
document type
citation
dois
  1. 10.1016/S1470-2045(21)00006-1
electronic publication date
display
2021 Mar 8
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33705695
immutable id
pubmed:33705695@017e8fe4c1f1cdf42aacde5a96fb73acd93ac76df15499001cc3e1ff068b9fca
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
439-449
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Apr;22(4):412-413. doi: 10.1016/S1470-2045(21)00024-3.
    note
    Source null
    related pmid
    33705694
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Jun;22(6):e230. doi: 10.1016/S1470-2045(21)00181-9.
    note
    Source null
    related pmid
    34087139
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Jun;22(6):e231. doi: 10.1016/S1470-2045(21)00187-X.
    note
    Source null
    related pmid
    34087140
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2021 Jun;22(6):e232. doi: 10.1016/S1470-2045(21)00277-1.
    note
    Source null
    related pmid
    34087141
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2021 Jun;22(6):e233. doi: 10.1016/S1470-2045(21)00294-1.
    note
    Source null
    related pmid
    34087142
    relationship
    Comment in
outcomes validated
false
pmid
33705695
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
0fe90263b93e137c7be64ce8a4598892090d5f87a44c45588b30fa893eaa3eaf
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Apr
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33705695/
title
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice